PE20191106A1 - Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1 - Google Patents

Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1

Info

Publication number
PE20191106A1
PE20191106A1 PE2019001193A PE2019001193A PE20191106A1 PE 20191106 A1 PE20191106 A1 PE 20191106A1 PE 2019001193 A PE2019001193 A PE 2019001193A PE 2019001193 A PE2019001193 A PE 2019001193A PE 20191106 A1 PE20191106 A1 PE 20191106A1
Authority
PE
Peru
Prior art keywords
antibodies
human
antibody
tim
combine
Prior art date
Application number
PE2019001193A
Other languages
English (en)
Inventor
Yiwen Li
Yi Zhang
Original Assignee
Lilly Co Eli
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Innovent Biologics Suzhou Co Ltd filed Critical Lilly Co Eli
Publication of PE20191106A1 publication Critical patent/PE20191106A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un anticuerpo anti-TIM3 humana (SEQ ID NO:1) en combinacion simultanea, separada o secuencial con una cantidad eficaz de un anticuerpo anti-PD-1. En donde el anticuerpo anti-PD1 humana es nivolumab o pembrolizumab. Estos anticuerpos se fijan a la proteina 3 que contiene el dominio de mucina y el dominio de inmunoglobulina de los linfocitos T humanos. Siendo util para el tratamiento del cancer como el melanoma, cancer de pulmon, entre otros; con agentes quimioterapeuticos y radiacion ionizante.
PE2019001193A 2016-12-08 2017-12-04 Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1 PE20191106A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662431480P 2016-12-08 2016-12-08
PCT/US2017/064480 WO2018106588A1 (en) 2016-12-08 2017-12-04 Anti-tim-3 antibodies for combination with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
PE20191106A1 true PE20191106A1 (es) 2019-08-23

Family

ID=60991520

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001193A PE20191106A1 (es) 2016-12-08 2017-12-04 Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1

Country Status (24)

Country Link
US (1) US11352424B2 (es)
EP (1) EP3551662A1 (es)
JP (1) JP6839772B2 (es)
KR (1) KR20190076029A (es)
CN (1) CN110267988A (es)
AR (1) AR110203A1 (es)
AU (1) AU2017372709A1 (es)
BR (1) BR112019009617A2 (es)
CA (1) CA3043763A1 (es)
CL (1) CL2019001459A1 (es)
CO (1) CO2019005846A2 (es)
CR (1) CR20190266A (es)
DO (1) DOP2019000142A (es)
EA (1) EA201991156A1 (es)
EC (1) ECSP19040905A (es)
IL (1) IL267025A (es)
JO (1) JOP20190133A1 (es)
MA (1) MA48604A (es)
MX (1) MX2019006723A (es)
PE (1) PE20191106A1 (es)
PH (1) PH12019501253A1 (es)
TN (1) TN2019000159A1 (es)
TW (1) TWI648065B (es)
WO (1) WO2018106588A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
PL3443009T3 (pl) 2016-04-12 2022-01-31 Symphogen A/S Przeciwciała i kompozycje anty-tim-3
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CA3030765A1 (en) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JP2020513009A (ja) 2017-04-05 2020-04-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐｄ−１、ｔｉｍ−３、およびｌａｇ−３を標的とする併用治療
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
AU2018346955B2 (en) 2017-10-13 2024-08-29 Harpoon Therapeutics, Inc. B cell maturation antigen binding proteins
EP3819313A4 (en) * 2018-07-03 2021-09-01 L&L Biopharma Co., Ltd. BISPECIFIC ANTIBODIES AND ITS USE
EP3823988A1 (en) * 2018-07-19 2021-05-26 Eli Lilly and Company Bispecific antibodies targeting immune checkpoints
WO2020038355A1 (zh) * 2018-08-20 2020-02-27 江苏恒瑞医药股份有限公司 Tim-3抗体在制备治疗肿瘤的药物中的用途
IL281683B2 (en) 2018-09-25 2023-04-01 Harpoon Therapeutics Inc dll3 binding proteins and methods of use
CA3126133A1 (en) * 2019-01-11 2020-07-16 Eli Lilly And Company Tim-3 antibodies and combinations with other checkpoint inhibitors for the treatment of cancer
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
WO2021024020A1 (en) 2019-08-06 2021-02-11 Astellas Pharma Inc. Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
WO2021175191A1 (zh) * 2020-03-02 2021-09-10 信达生物制药(苏州)有限公司 抗tim-3抗体及其用途
JP2023520772A (ja) * 2020-03-26 2023-05-19 キュアイミューン セラピューティクス インク． 抗ｐｄ－１抗体及び使用の方法
WO2022008519A1 (en) 2020-07-07 2022-01-13 BioNTech SE Therapeutic rna for hpv-positive cancer
WO2022135667A1 (en) 2020-12-21 2022-06-30 BioNTech SE Therapeutic rna for treating cancer
WO2022135666A1 (en) 2020-12-21 2022-06-30 BioNTech SE Treatment schedule for cytokine proteins
TW202245808A (zh) 2020-12-21 2022-12-01 德商拜恩迪克公司 用於治療癌症之治療性ｒｎａ
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
TW202333802A (zh) 2021-10-11 2023-09-01 德商拜恩迪克公司 用於肺癌之治療性rna(二)
WO2024126457A1 (en) 2022-12-14 2024-06-20 Astellas Pharma Europe Bv Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091631A1 (en) 2002-01-30 2022-11-23 The Brigham and Women's Hospital, Inc. A tim-3 binding molecule for use in the treatment of a disease
WO2011155607A1 (ja) * 2010-06-11 2011-12-15 協和発酵キリン株式会社 抗ｔｉｍ－３抗体
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8841418B2 (en) * 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
CN103721255A (zh) * 2014-01-07 2014-04-16 苏州大学 共同阻断pd-1和tim-3信号通路在抗胃癌治疗中的用途
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
WO2016007513A1 (en) 2014-07-07 2016-01-14 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
WO2016068803A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Anti-tim-3 antibodies
MA41867A (fr) * 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)

Also Published As

Publication number Publication date
PH12019501253A1 (en) 2019-12-11
AU2017372709A1 (en) 2019-05-16
BR112019009617A2 (pt) 2019-08-13
CA3043763A1 (en) 2018-06-14
JOP20190133A1 (ar) 2019-06-02
DOP2019000142A (es) 2019-08-15
IL267025A (en) 2019-07-31
CL2019001459A1 (es) 2019-11-15
CO2019005846A2 (es) 2019-06-19
EP3551662A1 (en) 2019-10-16
JP6839772B2 (ja) 2021-03-10
EA201991156A1 (ru) 2019-11-29
US11352424B2 (en) 2022-06-07
CR20190266A (es) 2019-08-22
TW201831198A (zh) 2018-09-01
US20190276534A1 (en) 2019-09-12
TN2019000159A1 (en) 2020-10-05
CN110267988A (zh) 2019-09-20
AR110203A1 (es) 2019-03-06
MX2019006723A (es) 2019-08-22
WO2018106588A1 (en) 2018-06-14
TWI648065B (zh) 2019-01-21
MA48604A (fr) 2020-03-18
JP2020504171A (ja) 2020-02-06
KR20190076029A (ko) 2019-07-01
ECSP19040905A (es) 2019-06-30

Similar Documents

Publication Publication Date Title
PE20191106A1 (es) Anticuerpos anti-tim-3 para combinar con anticuerpos anti-pd-1
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
CO2019012210A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CO2017005650A2 (es) Anticuerpos anti-interleucina-33
UY38236A (es) COMBINACIONES FARMACÉUTICAS QUE CONTIENEN EL ANTICUERPO ANTI-CD38, ASOCIADO CON LOS ANTICUERPOS BIOESPECÍFICOS BCMAxCD3 O GPRC5DxCD3 O CD19xCD3
CO2019001646A2 (es) Anticuerpos de anti-tim-3
ECSP19078414A (es) Anticuerpos anti-cd33 y métodos para utilizarlos
PE20161392A1 (es) Combinacion de lenalidomida y constructo de polipeptido, y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CO2020010277A2 (es) Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
EA202190542A1 (ru) Сконструированные биспецифические белки
EA202191784A1 (ru) Активируемые маскированные связывающие белки к ctla4
EA202190235A1 (ru) Антитела к cd33 и способы их применения
UY37757A (es) Composiciones, procedimientos y/o kits que comprenden un dominio extracelular de cd38 humano recombinante
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
PE20191319A1 (es) Anticuerpos novedosos contra el factor xi y sus usos
AR111193A1 (es) Anticuerpos biespecíficos que se unen con ligando 1 de muerte celular programada humana (pd-l1) y con la proteína 3 que contiene dominio de inmunoglobulina y mucina de células t (tim-3)
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения
AR107083A1 (es) Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
EA202091600A1 (ru) Конструкция на основе биспецифического антитела, направленная на muc17 и cd3
AR113757A1 (es) Anticuerpos anti-cd38 y métodos de uso
AR106996A1 (es) Anticuerpos monoclonales anti-ctla4 humano quiméricos y humanizados y sus usos